Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for its traditional Chinese medicine "Cough Orange Granules" to conduct clinical trials for new indications [1] Summary by Categories Product Development - The approval allows the company to conduct clinical trials for the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing the lungs [1] - "Cough Orange Granules" is already a product that has been produced and sold by the company, previously classified as a national secondary protected traditional Chinese medicine [1] Regulatory Approval - The clinical trial application was deemed to meet the requirements for drug registration, indicating a positive regulatory response to the company's submission [1] - The approval is based on the latest clinical research and expert consensus, showcasing the company's commitment to expanding the therapeutic applications of its products [1]